Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

  • Technology appraisal guidance
  • TA1147
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

Guidance into practice